Archives

  • Volume 2, Issue 1, Spring 2025

    • The Role of ctDNA in Breast Cancer: Prognosis and Clinical Utility
    • Clinical Considerations for the Management of Advanced PD-L1 ≥50% Non-small Cell Lung Cancer In 2025: Should All Patients Be Treated the Same?
    • Current Approaches and Future Directions for the Treatment of Solid Tumour Brain Metastases
    • The Role of Biomarkers in Upper Gastrointestinal Cancers
    • Advances in Adjuvant Therapy for High-Risk Breast Cancer: A Canadian Clinical Approach

  • Volume 1, Issue 3, Fall 2024

    • First-line Treatment Selection for Advanced Hepatocellular Carcinoma
    • Prostate-specific Membrane Antigen (PSMA): A Diagnostic and Therapeutic Target in Advanced Prostate Cancer
    • Breast Cancer Survivorship
    • Tailored Approaches and Patient-centered Care: The Current Landscape of Neoadjuvant Therapy in Rectal Cancer
    • Antibody-Drug Conjugates in the Management of Advanced Urothelial Carcinoma

  • Volume 1, Issue 2, Summer 2024

    • Current and Emerging Treatment Options for HER2-Positive Gastroesophageal Cancer
    • Current Uses and Pitfalls of Liquid Biopsy in NSCLC
    • From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer
    • Survivorship Issues in Testicular Cancer
    • An Evolving Paradigm in Borderline Resectable and Locally Advanced Pancreatic Cancer: Current Strategies and Opportunities for the Future

  • Volume 1, Issue 1, March 2024

    • The Evolution of PARP Inhibitors in Prostate Cancer
    • KRAS Inhibitors in Lung Cancer: Current Strategies and Future Approaches
    • Early Age Onset Colorectal Cancer: A Canadian Perspective
    • Revolutionizing Breast Imaging: Artificial Intelligence’s Role in Precisely Differentiating Benign from Malignant Lesions
    • A Review of EGFR-Mutant Non‑Small Cell Lung Cancer (NSCLC) in 2024